News and updates from IPOX®, including media mentions, interviews, research and press releases.
In a Reuters article on Navan’s planned $6.45 billion U.S. IPO, IPOX® CEO Josef Schuster commented on the impact of the ongoing U.S. government shutdown on IPO sentiment. Schuster noted that while optimism remains, “heightened volatility” and regulatory delays may weigh on demand, urging issuers to remain flexible with offering terms.
In a Reuters feature on how companies are navigating IPO plans during the U.S. government shutdown, IPOX® Research Associate Lukas Muehlbauer explained why biotech firms like MapLight are seizing this favorable market window despite regulatory delays. Muehlbauer noted that MapLight aims to get ahead of the SEC backlog, though the 20-day pricing lock limits flexibility. He added that biotech firms’ urgent funding needs make them prime candidates for this route.
Reuters reports that MapLight Therapeutics is targeting a $704.3 million valuation in its U.S. IPO, reflecting renewed investor appetite for biotech offerings. IPOX® CEO Josef Schuster described the move as “opportunistic”, citing the strong market climate for IPOs and heightened M&A activity in the sector. Schuster added that MapLight’s promising drug candidates and market momentum are likely to attract significant investor interest.
In a recent Reuters article, IPOX® CEO Josef Schuster commented on Cerebras Systems’ decision to withdraw its planned U.S. IPO, following the company’s $1.1 billion funding round. Schuster noted the move was “no surprise” given the recent capital raise, emphasizing it was a strategic decision rather than a reflection of market weakness, adding that U.S. IPO sentiment remains exceptionally strong amid renewed investor enthusiasm for AI-related offerings.
A U.S. government shutdown has halted SEC IPO processing, creating uncertainty just as the market was rebounding. While some deals may face delays, IPOX® research analyst Lukas Muehlbauer emphasized that strong investor demand and inflows into IPO-focused funds should sustain momentum once operations resume. “The best after-market performance in years will continue to lure companies to the market,” he noted.
Education provider Phoenix Education Partners, owner of the University of Phoenix, is targeting a valuation of up to $1.17B in its planned U.S. IPO. Backed by Apollo Global and Vistria Group, the firm seeks to raise $140.3M with shares priced between $31–33, listing on the NYSE under "PXED." IPOX® CEO Josef Schuster noted strong sentiment for U.S. IPOs, highlighting differences in PE-backed deals. The offering reflects renewed sponsor-led listing momentum.
Wealthfront has filed for a U.S. IPO after reporting $308.9 million in 2025 revenue, up from $216.7 million a year earlier. Commenting on the filing, IPOX® CEO Josef Schuster noted that the U.S. IPO market remains “extremely healthy” going into Q4 but cautioned that investor appetite may be tested if pricing is too aggressive, citing recent post-listing performance of Chime and eToro.
Reuters highlights IPOX® CEO Josef Schuster’s commentary on Alliance Laundry’s planned $4.34 billion IPO. Backed by BDT & MSD Partners, the company aims to raise up to $751 million on the NYSE under “ALH.” Schuster noted that the inclusion of PE-backed firms broadens U.S. IPO deal flow and that cornerstone investor demand underscores the IPO’s medium- to long-term appeal.
Electric aircraft maker Beta Technologies has filed for a U.S. IPO, aiming to trade on the NYSE under the ticker BETA. In coverage by Reuters, Kat Liu, Vice President at IPOX®, noted: “Beta's IPO plays into two narratives that are resonating with investors: the long-term electrification trend and renewed appetite for selective growth stories.” The listing highlights growing investor interest in sustainable aviation and clean mobility solutions.